Two decades of studies of intraperitoneal therapy for persistent or recurrent ovarian carcinoma have clearly shown that the procedure is generally safe, particularly in experienced users. Further, ...

In this issue of the Journal of Clinical Oncology, three experienced and respected European clinical researchers present their viewpoint that intraperitoneal (IP) chemotherapy remains experimental in ...

Surgery and standard intravenous chemotherapy with a platinum-taxane combination induces complete remission in the majority of patients with newly diagnosed ovarian cancer. Most patients will ...

Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations ...

Intraperitoneal chemotherapy was associated with long-term survival benefits compared with IV chemotherapy in patients with advanced ovarian cancer, according to retrospective study results. The ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced ovarian cancer who underwent intraperitoneal chemotherapy were 17% more likely to live ...

Oncologist Don Dizon explains the advantages of intraperitoneal therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment. Intraperitoneal ...

PATIENTS undergoing peritoneal dialysis frequently require antibiotic therapy for intraperitoneal and systemic infections. Since information concerning transperitoneal movement of antibiotics is ...

Interest in the intraperitoneal delivery of chemotherapy to patients with ovarian cancer with minimal residual disease following initial cytoreductive surgery has been rekindled with the recent ...